Case report

A 55-year-old post-menopausal female presented to George Regional Hospital in 2017 with a sinister left breast mass, suggestive of a cT4aN2 breast cancer. She had no family history of breast cancer and was not using hormone replacement therapy. Mammography demonstrated a Breast Imaging-Reporting and Data System (BIRADS) 5 lesion (Figure 1) in the left breast (> 95% probability of malignancy) which was biopsied under ultrasound guidance confirming an infiltrating ductal carcinoma. The biomarkers were oestrogen receptor (ER) positive (Allred score 7/8), progesterone receptor (PR) positive (Allred score 6/8) and human epidermal growth factor receptor 2 (HER2-neu) 2+ positive. Gene amplification was performed to ascertain the true status of the HER2-neu receptor which was negative. No staging examinations were done at this stage.

She defaulted treatment and re-presented in November 2019 at which stage she was referred to oncology for neoadjuvant chemotherapy. She was restaged as T4cN2M0. Due to an adverse reaction to paclitaxel, she defaulted systemic treatment in December 2019.

A left modified radical mastectomy and axillary clearance was performed in March 2020, three months after defaulting neoadjuvant chemotherapy. Histology demonstrated extensive invasive carcinoma of no special type which had invaded the left pectoralis muscle. Six out of eight lymph nodes removed demonstrated metastatic disease and there was only a partial treatment response to neoadjuvant chemotherapy. The E-cadherin was positive, confirming ductal origin of the tumour and the immunohistochemistry demonstrated strong oestrogen receptor positivity (Allred score 6/8). Both the progesterone and HER2-neu receptors were negative. She was started on oral chemotherapy and had left chest-wall radiation.

In May 2020, she presented to the ophthalmology department with a painless, fixed right inferolateral orbital rim mass (Figure 2). There was no sign of locoregional breast cancer recurrence. She was referred for a contrast enhanced
computed tomography (CT) scan of the brain and orbits. The CT scan (Figure 3) of the right orbit demonstrated a homogeneously enhancing mass localised to the fat inferior to the right globe. The mass extended into the extraconal space along fascial planes but did not invade the rectus muscles or globe.

Excision biopsy of this mass demonstrated metastatic disease. The immunohistochemistry favoured a breast origin with a positive E-cadherin stain (Figure 4) and strong ER positivity (Allred score 8/8) (Figure 5), PR positivity (Allred score 6/8) and a HER2 1+ score (negative). She was restaged with a chest X-ray, liver ultrasound and nuclear medicine bone scan.

Bleomycin injections were commenced by ophthalmology in conjunction with her oncology management, which consisted of palliative systemic treatment in the form of arimidex. Unfortunately, she had a poor response to the palliative endocrine treatment and presented in November 2020 with a bony metastasis to the left tibia on X-rays. She was then again lost to follow-up.
In March 2021, she presented with sudden onset of bilateral lower limb paralysis and CT scan confirmed extensive spinal metastases.

**Discussion**

Orbital metastasis (OM) is a rare finding in systemic cancer, with few case reports and less frequent elucidation of the primary tumour. Histologically confirmed OM are diagnosed once or twice at larger academic centres per year and most of the literature is from single case reports.

Breast carcinoma is the most likely primary tumour, accounting for 29–35% of all tumours in the orbit. In a series by Raap et al., just over 25% of patients with breast carcinoma and OM, presented initially with OM.

Other primary sites, in order of metastatic sequence, include lung, prostate, kidney, melanoma, gastrointestinal tumours and hepatocellular carcinoma. It is often difficult to make the diagnosis of OM and elucidate the primary site clinically and radiologically; therefore, histopathology with immunohistochemistry is essential.

Invasive lobular carcinoma is more likely to cause OM than invasive ductal carcinoma. The hypothesis is that there is a higher amount of oestrogen produced by the eye, which leads to a greater prediction of ILC to metastasise to the orbit. Blohmer et al. also demonstrated that there are a considerable number of patients with bilateral OM secondary to invasive lobular carcinoma. In our patient, the excision biopsy from the right orbital tumour demonstrated a similar morphology to the mastectomy specimen, which revealed invasive carcinoma of no special type. However, the E-cadherin staining was less strong and crisp than the internal control and compared to that of the mastectomy specimen. The tumour may have been a pleomorphic variant of invasive lobular carcinoma as 10% of invasive lobular carcinomas demonstrate retained E-cadherin staining. It is not possible to evolve from invasive carcinoma of no special type into an invasive lobular carcinoma. The rapid clinical progression is also in keeping with OM from breast carcinoma.

Cross-sectional imaging, especially magnetic resonance imaging (MRI), is valuable in characterising and determining the extent of disease which then supplements the ophthalmological findings and diagnosis. Critical information includes which intra-orbital structures are involved, perineural spread and intracranial extension. CT is less sensitive than MRI. However, differentiating non-neoplastic orbital infiltrating processes such as sarcoidosis from OM often poses a diagnostic challenge. It may be difficult on imaging to determine the principle orbital tissue site as the disease may have markedly infiltrated surrounding tissues. OM from breast carcinoma are diffuse with irregular growth along rectus muscles and fascial planes and form ill-defined orbital masses. In our patient, the CT scan of the right orbit demonstrated a well-defined enhancing mass with growth along the fat and fascial planes, which did not extend along the rectus muscles.

OM may be diagnosed incidentally initially by PET CT. PET CT can also assist in detecting the primary tumour and other metastases.

OM secondary to breast carcinoma do not occur in isolation. Bone and the central nervous system are the most common other metastatic sites in these patients. Our patient presented with extensive metastases to the spine. Treatment options are all palliative as OM occurs as part of disseminated disease. These include surgical resection, local irradiation, chemotherapy or endocrine therapy.

OM from breast carcinoma is characterised by very rapid progression and a poor prognosis. The average survival is 31 months after presentation. The outcome in our patient is not known as she was lost to follow-up.

**Ethical approval**

Ethics approval was obtained from the George Hospital Ethics Committee on 24 February 2021.

**REFERENCES**


